ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
Gross Profit
ReShape Lifesciences Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Gross Profit
$5.5m
|
CAGR 3-Years
112%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Gross Profit
$8.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Boston Scientific Corp
NYSE:BSX
|
Gross Profit
$10.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Stryker Corp
NYSE:SYK
|
Gross Profit
$13.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Abbott Laboratories
NYSE:ABT
|
Gross Profit
$22.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Gross Profit
$4.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
See Also
What is ReShape Lifesciences Inc's Gross Profit?
Gross Profit
5.5m
USD
Based on the financial report for Dec 31, 2023, ReShape Lifesciences Inc's Gross Profit amounts to 5.5m USD.
What is ReShape Lifesciences Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
9%
Over the last year, the Gross Profit growth was -18%. The average annual Gross Profit growth rates for ReShape Lifesciences Inc have been 112% over the past three years , 9% over the past five years .